Selection of oral bioavailability enhancing formulations during drug discovery

Abstract

The objective of this paper was to identify oral bioavailability enhancing approaches for a poorly water-soluble research compound during drug discovery stages using minimal amounts of material.

LCQ789 is a pBCS (preclinical BCS) Class II compound with extremely low aqueous solubility (<1 µg/mL) and high permeability, therefore, resulting in very low oral bioavailability in preclinical species (rats and dogs). A number of solubility and/or dissolution enhancing approaches including particle size reduction, solid dispersions, lipid-based formulations and co-crystals, were considered in order to improve the compound’s oral bioavailability. High-Throughput Screening (HTS) and in silico modeling (GastroPlus™) were utilized to minimize the compound consumption in early discovery stages. In vivo evaluation of selected physical form and formulation strategies was performed in rats and dogs. Amongst the formulation strategies, optimized solid dispersion and lipid-based formulation provided significant improvement in drug dissolution rate and hence, oral bioavailability. In addition, a significant impact of physical form on oral bioavailability of LCQ789 was observed. In conclusion, a thorough understanding of not only the formulation technique but also the physical form of research compounds is critical to ensure physical stability, successful pharmacokinetic (PK) profiling and early developability risk assessment.

Keywords::

• Physical form
• high-throughput screening
• co-crystal
• solid dispersion
• lipid-based delivery
• bioavailability

Acknowledgements

The authors would like to thank Dr. Jun Han for valuable scientific discussions, Dr. Tsu-Han Lin and WenYu Hu for providing in vivo exposure data and Dr. Beta Sweryda-Krawiec for co-crystal work.

Declaration of interest

The authors declare no conflicts of interest.